Patients with mild cognitive impairment and a reduced CSF Aβ1-42 protein progress rapidly to Alzheimer's disease

Patients with mild cognitive impairment and a reduced CSF Aβ1-42 protein progress rapidly to Alzheimer's disease

Introduction: Some studies have shown that CSF amyloid-beta 1-42 (Aβ1-42), total tau (T-tau) and tau phosphorylated at threonine 181 (P-tau181p) proteins are useful diagnostic markers for distinguishing between clinically stable mild cognitive impairment (MCI) patients and those who will develop Alz...

Full description

Bibliographic Details
Main Authors:	J.A. Monge-Argilés, J. Sánchez-Payá, C. Muñoz-Ruiz, A. Pampliega-Pérez, M.J. Gómez-López, E. Rodríguez Borja, J. Montoya-Gutiérrez, C. Leiva-Santana
Format:	Article
Language:	English
Published:	Elsevier España 2012-01-01
Series:	Neurología (English Edition)
Online Access:	http://www.sciencedirect.com/science/article/pii/S2173580812000119

Similar Items

Pacientes con deterioro cognitivo leve y reducción de la proteína Aβ1-42 en LCR evolucionan rápidamente a enfermedad de Alzheimer
by: J.A. Monge-Argilés, et al.
Published: (2012-01-01)

A comparison of early diagnostic utility of Alzheimer disease biomarkers in magnetic resonance and cerebrospinal fluid
by: J.A. Monge Argilés, et al.
Published: (2014-09-01)

Validity of CSF alpha-synuclein to predict psychosis in prodromal Alzheimer's disease
by: Sonia Monge-García, et al.
Published: (2023-05-01)

Pathophysiological subtypes of mild cognitive impairment due to Alzheimer’s disease identified by CSF proteomics
by: Daniela Moutinho, et al.
Published: (2024-04-01)

CSF Biomarkers in the Early Diagnosis of Mild Cognitive Impairment and Alzheimer’s Disease
by: Vasileios Papaliagkas, et al.
Published: (2023-05-01)

Comparación de la capacidad diagnóstica precoz de los biomarcadores de la enfermedad de Alzheimer en resonancia magnética cerebral y líquido cefalorraquídeo
by: J.A. Monge Argilés, et al.
Published: (2014-09-01)

Relation between Alpha-Synuclein and Core CSF Biomarkers of Alzheimer’s Disease
by: Victoria Monge-García, et al.
Published: (2021-09-01)

Differential diagnosis of mild cognitive impairment of Alzheimer’s disease by Simoa p-tau181 measurements with matching plasma and CSF
by: Ling Wu, et al.
Published: (2024-01-01)

Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics.
by: Eugenia Trushina, et al.
Published: (2013-01-01)

Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers
by: Nho, K, et al.
Published: (2018)

CSF Aβ42 and Aβ42/Aβ40 Ratio in Alzheimer’s Disease and Frontotemporal Dementias
by: Vasilios C. Constantinides, et al.
Published: (2023-02-01)

Inverse association between CSF Aβ 42 levels and years of education in mild form of Alzheimer's disease: The cognitive reserve theory
by: Julien Dumurgier, et al.
Published: (2010-11-01)

Improving CSF biomarkers’ performance for predicting progression from Mild Cognitive Impairment to Alzheimer’s disease: a meta-analysis
by: Daniel eFerreira, et al.
Published: (2014-10-01)

Blood and CSF chemokines in Alzheimer’s disease and mild cognitive impairment: a systematic review and meta-analysis
by: Futao Zhou, et al.
Published: (2023-06-01)

Evaluation of Synaptic and Axonal Dysfunction Biomarkers in Alzheimer’s Disease and Mild Cognitive Impairment Based on CSF and Bioinformatic Analysis
by: Maciej Dulewicz, et al.
Published: (2022-09-01)

CSF sTREM2 in delirium—relation to Alzheimer’s disease CSF biomarkers Aβ42, t-tau and p-tau
by: Kristi Henjum, et al.
Published: (2018-11-01)

ADAM10 Plasma and CSF Levels Are Increased in Mild Alzheimer’s Disease
by: Izabela Pereira Vatanabe, et al.
Published: (2021-02-01)

Association of CSF GAP-43 and <i>APOE</i> ε4 with Cognition in Mild Cognitive Impairment and Alzheimer’s Disease
by: Yueli Zhu, et al.
Published: (2022-12-01)

Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer's disease
by: Blennow Kaj, et al.
Published: (2011-10-01)

Selection of subjects for clinical trials in Alzheimer’s disease and mild cognitive impairment with machine learning analysis of MRI and CSF biomarkers
by: Escudero Javier, et al.
Published: (2011-12-01)

β-Amyloid (1–42) Levels in Cerebrospinal Fluid and Cerebral Atrophy in Mild Cognitive Impairment and Alzheimer’s Disease
by: Elmar Kaiser, et al.
Published: (2011-11-01)

CSF T-Tau/Aβ42 predicts white matter microstructure in healthy adults at risk for Alzheimer's disease.
by: Barbara B Bendlin, et al.
Published: (2012-01-01)

Association Analysis of Peripheral and CSF Biomarkers in Late Mild Cognitive Impairment
by: Tao Zhang, et al.
Published: (2020-08-01)

Correlates of Subjective and Mild Cognitive Impairment: Depressive Symptoms and CSF Biomarkers
by: Ramune Grambaite, et al.
Published: (2013-09-01)

Metabolomic profiling of CSF and blood serum elucidates general and sex-specific patterns for mild cognitive impairment and Alzheimer’s disease patients
by: Georgy Berezhnoy, et al.
Published: (2023-08-01)

Effects of baseline CSF α-synuclein on regional brain atrophy rates in healthy elders, mild cognitive impairment and Alzheimer's disease.
by: Niklas Mattsson, et al.
Published: (2013-01-01)

CSF Extracellular Vesicle Aβ42 and Tau/Aβ42 Ratio Are Associated with Cognitive Impairment in Older People with HIV
by: Debjani Guha, et al.
Published: (2023-12-01)

The Persistence of the Self over Time in Mild Cognitive Impairment and Alzheimer's Disease
by: Lynette J. Tippett, et al.
Published: (2018-02-01)

CSF neurochemical profile and cognitive changes in Parkinson’s disease with mild cognitive impairment
by: Federico Paolini Paoletti, et al.
Published: (2023-04-01)

Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six-year follow-up study.
by: Sebastian Palmqvist, et al.
Published: (2012-01-01)

Writing Impairments in Japanese Patients with Mild Cognitive Impairment and with Mild Alzheimer's Disease
by: Atsuko Hayashi, et al.
Published: (2015-09-01)

Spatial inhibition of return is impaired in mild cognitive impairment and mild Alzheimer's disease.
by: Xiong Jiang, et al.
Published: (2021-01-01)

A single-domain antibody detects and neutralises toxic Aβ42 oligomers in the Alzheimer’s disease CSF
by: Alessandra Bigi, et al.
Published: (2024-01-01)

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
by: Oskar Hansson, et al.
Published: (2019-04-01)

Volume transmission of CSF: complications in aging and Alzheimer's disease
by: Duncan J, et al.
Published: (2004-12-01)

Abnormal visual search in mild cognitive impairment and Alzheimer's disease.
by: Tales, A, et al.
Published: (2005)

One-carbon metabolism, cognitive impairment and CSF measures of Alzheimer pathology: homocysteine and beyond
by: Loïc Dayon, et al.
Published: (2017-06-01)

Neuroanatomy of impaired self-awareness in Alzheimer's disease and mild cognitive impairment.
by: Zamboni, G, et al.
Published: (2013)

Neuroanatomy of impaired self-awareness in Alzheimer's disease and mild cognitive impairment
by: Zamboni, G, et al.
Published: (2013)

P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
by: Michelle R. Campbell, et al.
Published: (2021-01-01)